Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RLMD
RLMD logo

RLMD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Relmada Therapeutics Inc (RLMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
6.330
1 Day change
0.80%
52 Week Range
8.000
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

RLMD is not a good buy right now for a beginner, long-term investor with $50,000-$100,000 to deploy. The stock has some supportive signs, including bullish moving averages and insider buying, but the overall setup is not strong enough to justify a clear long-term buy today. With no recent news catalyst, no solid financial snapshot, and no proprietary buy signal, the better call is to wait rather than buy immediately.

Technical Analysis

Price is 6.27 and essentially flat versus the previous close of 6.28, while the broader market was also slightly weak. Technically, the setup is mixed but mildly constructive: SMA_5 > SMA_20 > SMA_200 indicates an upward trend structure, and the MACD histogram is slightly positive at 0.00568, though contracting, which suggests momentum is fading. RSI_6 at 35.225 is neutral-to-weak, not yet oversold enough to signal a strong rebound. The current price is below the pivot at 6.682 and below R1 at 7.009, so the stock has not yet confirmed strength above near-term resistance. Short-term modeled trend is weak to flat, with only a 40% chance of a 0.3% move up next day and a -2.89% expectation over the next month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is strongly bullish on paper because call open interest is far larger than put open interest, with a put-call ratio of 0.03. Option volume also shows a 0.0 put-call ratio, reinforcing a heavily call-skewed setup. However, total option volume is very low at 18 contracts, so the sentiment signal is positive but not very robust. Implied volatility is 54.38%, below the 5-day and 10-day averages, suggesting volatility has cooled from recent levels.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
5

Positive Catalysts

  • H.C. Wainwright initiated coverage with a Buy rating and a $12 price target, which is substantially above the current price. Insider buying has also increased sharply, up 1133.44% over the last month, which is a notable positive signal. The options market is heavily call-skewed, suggesting traders are positioning bullishly. The company’s NDV-01 program is being viewed favorably as a differentiated delivery platform.

Neutral/Negative Catalysts

  • There is no news in the recent week, so no immediate event-driven catalyst is supporting the share price. Hedge funds are neutral, with no significant trading trends over the last quarter. Financial snapshot data was unavailable, limiting confidence in the fundamental picture. The stock also shows a weak short-term modeled next-month return of -2.89%, and technical momentum is not strong enough to confirm a sustained breakout.

Financial Performance

Latest quarter financial data was not available due to an error, so a full growth assessment cannot be made. Because the latest quarter season is unavailable, there is no reliable evidence here to support a fundamental buy based on revenue, earnings, or margin acceleration.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is constructive. The latest coverage from H.C. Wainwright on 2026-06-18 initiated RLMD as Buy with a $12 target, implying meaningful upside from current levels. Wall Street pros appear supportive on the story and pipeline potential, but the view is based on a development-stage thesis rather than demonstrated operating performance. The pro case is the bullish analyst initiation and higher target; the con side is the lack of broader analyst support, no recent catalyst, and limited fundamental visibility.

Wall Street analysts forecast RLMD stock price to rise
2 Analyst Rating
Wall Street analysts forecast RLMD stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.280
sliders
Low
9
Averages
9.5
High
10
Current: 6.280
sliders
Low
9
Averages
9.5
High
10
H.C. Wainwright
Buy
initiated
$12
AI Analysis
2026-06-18
Reason
H.C. Wainwright
Price Target
$12
AI Analysis
2026-06-18
initiated
Buy
Reason
H.C. Wainwright initiated coverage of Relmada Therapeutics with a Buy rating and $12 price target. The company's NDV-01 is a "differentiated" sustained-release intravesical formulation for non-muscle invasive bladder cancer, the analyst tells investors in a research note. The firm believes NDV-01 is a next-generation delivery platform for a "familiar and increasingly validated" intravesical chemotherapy backbone rather than a wholly novel therapeutic modality.
Piper Sandler
Overweight
initiated
$12
2026-03-24
Reason
Piper Sandler
Price Target
$12
2026-03-24
initiated
Overweight
Reason
Piper Sandler initiated coverage of Relmada Therapeutics with an Overweight rating and $12 price target. The firm says the company is advancing NDV-01, a novel intravesicle treatment for non-muscle invasive bladder cancer with "several key advantages" versus existing options. These include the benefits of chemo combination therapy and sustained-release formulation for increased exposure, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for RLMD
Unlock Now

People Also Watch